

CLAIMS

51. A gene delivery vehicle comprising a nucleic acid molecule
encoding apoptin-like activity.

52. A gene delivery vehicle according to claim 1 additionally
comprising a modified translation initiation site directly
upstream the ATG-initiation codon of said nucleic acid
molecule.

53. A gene delivery vehicle according to claim 2 wherein said
translation initiation site comprises the nucleic acid
sequence GCAAAC.

10 54. A gene delivery vehicle comprising a nucleic acid molecule
encoding VP2-like activity.

15 55. A gene delivery vehicle according to claim 4 additionally
comprising a modified translation initiation site directly
upstream the ATG-initiation codon of said nucleic acid
molecule.

6 56. A gene delivery vehicle according to any of claims 1 to 3
additionally comprising a nucleic acid molecule encoding VP2-
like activity.

20 57. A gene delivery vehicle according to claim 6 additionally
comprising a modified translation initiation site directly
upstream the ATG-initiation codon of the nucleic acid
molecule encoding VP2-like activity.

58. A gene delivery vehicle according to any of claims 1 to 7
which is a virus.

25 59. A gene delivery vehicle according to claim 8 which is a
replication-defective virus.

60. A gene delivery vehicle according to claim 8 or 9 which
is an adenovirus.

30 61. A gene delivery vehicle according to claim 8 or 9 which
is a retrovirus.

62. A gene delivery vehicle according to any of claims 1 to
31 which additionally comprises at least one target molecule

*sub 3
B*

~~13. A gene delivery vehicle according to claim 12 wherein the target molecule is reactive with a tumor cell surface receptor.~~

*sub 5
S*

~~14. A host cell comprising a gene delivery vehicle according to any of the claims 1-13.~~

*Sub 4
B*

~~15. A host cell according to claim 14 which is a helper or packaging cell.~~

~~16. A host cell according to claim 14 which is selected from the group of HEK;293, HER;911, PER.C6, Psi-2 and PA317 cells.~~

10a ~~17. Use of a gene delivery vehicle according to any of claims 1-13 in cancer treatment.~~

a ~~18. Use of a gene delivery vehicle according to claim 17 in combination with conventional (chemo)therapy.~~

a ~~19. Use of a gene delivery vehicle according to any of claims 1-13 for the treatment of hyperplasia, metaplasia and dysplasia.~~

a ~~20. Use of a gene delivery vehicle according to any of claims 1-13 in diagnosis.~~

20 ~~21. Use of a gene delivery vehicle according to claim 20 in the in vitro detection of transformed, or cancerous, or hyperplastic, metaplastic or dysplastic cells.~~

*AAC
B5*

Add E4